Oskare Capital

We are the first fund taking this approach and have a unique pipeline of deals The Fund will invest in startups across the entire value chain (from Seed to Patient) but will not invest in cannabis production or recreational cannabis

With a highly favorable legal and regulatory landscape in Europe, medical cannabis is a high growth market (€15 B in 2029) and will continue to disrupt the wider market of diseases addressable via the Endocannabinoid System (€438 B today) Promising new cannabinoid solutions under study for epilepsy, pain, spasticity, anxiety, and sleep oncology, cardiovascular conditions, Autism and Down's Syndrome among others Óskare Capital has identified a large number of companies in its dealflow pipeline with strong teams, disruptive IP and scalable technologies Management team based in Paris and London Best ESG practices and will not invest in recreational cannabis or cannabis production Investments in science, services and solutions with high barriers to entry Focus on scientific innovation and in generating solutions and tangible outcomes in the wellness and medical sectors for which there is strong scientific rationale to utilize cannabinoids The fund will prioritize opportunities that are protected by strong intellectual property “Only a subset of investors and entrepreneurs go into these spaces, but the size of the prize is massive”